Apellis Pharmaceuticals, Inc.

APLS

NASDAQ

Healthcare

Biotechnology

Waltham, MA, US705 employeesapellis.com

$40.44

+0.05(0.12%)

Mkt Cap $5.2B

$16.36

$40.41

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (44.4%), Syfovre (37.1%), Licensing And Other Revenue (11.1%).

8-K

Apellis Pharmaceuticals has entered into a definitive agreement to be acquired by Biogen Inc. for $41 per share upfront plus up to $4 per share in contingent value rights.

$5.2B

Market Cap

$1.0B

Revenue

$23M

Net Income

Employees705

Fundamentals

How The Business Makes Money

Revenue by Segment

Product44.4%($1.8B)

Syfovre37.1%($1.5B)

Licensing And Other Revenue11.1%($441M)

Empaveli Pegcetacoplan7.3%($292M)

Activity

What Changed Recently

Management Change

Mar 1, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February

Financial Results

Jan 11, 2026

Results of Operations and Financial Condition. On January 12, 2026, Apellis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing preliminary

Management Change+3 More

Mar 30, 2026

| Entry into a Material Definitive Agreement. | |---|---| Agreement and Plan of Merger On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation

Peer Companies

Company	Price	Change	Market Cap	P/E
SRRKScholar Rock Holding Corp...	$50.27	+1.87%	$5.8B	-13.3
CDTXCDTX	$221.38	+0.00%	$5.6B	—
KNSAKiniksa Pharmaceuticals, ...	$48.76	+1.31%	$3.6B	57.9
CPRXCatalyst Pharmaceuticals,...	$24.70	-0.48%	$3.0B	13.3
IDYAIDEAYA Biosciences, Inc.	$32.60	+0.37%	$2.9B	-24.7
BEAMBeam Therapeutics Inc.	$24.65	+1.78%	$2.5B	-32.4
ADPTAdaptive Biotechnologies ...	$14.84	+2.84%	$2.3B	-35.2
AGIOAgios Pharmaceuticals, In...	$35.17	+2.87%	$2.1B	-4.0

Analyst View

Company Profile

CIK0001492422

ISINUS03753U1060

CUSIP03753U106

Phone617 977 5700

Address100 Fifth Avenue, Waltham, MA, 02451, US

SEC EDGAR